Sarah L. Mott

3.6k total citations · 1 hit paper
186 papers, 2.4k citations indexed

About

Sarah L. Mott is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarah L. Mott has authored 186 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 55 papers in Surgery and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarah L. Mott's work include Bladder and Urothelial Cancer Treatments (31 papers), Urinary and Genital Oncology Studies (30 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Sarah L. Mott is often cited by papers focused on Bladder and Urothelial Cancer Treatments (31 papers), Urinary and Genital Oncology Studies (30 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Sarah L. Mott collaborates with scholars based in United States, Australia and United Kingdom. Sarah L. Mott's co-authors include Michael A. O’Donnell, Ryan L. Steinberg, Anna M. Button, Kenneth G. Nepple, James J. Mezhir, Aileen Clarke, Nick Black, Vignesh T. Packiam, S. Joglekar and Aeen Asghar and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sarah L. Mott

165 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

2023 60 citations Ian M. McElree, Ryan L. Steinberg et al. profile →

Peers

Countries citing papers authored by Sarah L. Mott

Since Specialization

Citations

This map shows the geographic impact of Sarah L. Mott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah L. Mott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah L. Mott more than expected).

Fields of papers citing papers by Sarah L. Mott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah L. Mott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah L. Mott. The network helps show where Sarah L. Mott may publish in the future.

Co-authorship network of co-authors of Sarah L. Mott

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah L. Mott. A scholar is included among the top collaborators of Sarah L. Mott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah L. Mott. Sarah L. Mott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer 2025 ·British Journal of Urology ·Ian M. McElree, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Vignesh T. Packiam, Michael A. O’Donnell	0
2	Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer 2024 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Ian M. McElree, Vignesh T. Packiam, Sarah L. Mott, Michael A. O’Donnell	4
3	ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA 2024 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Ian M. McElree, Sarah L. Mott, (unknown), (unknown), Ryan L. Steinberg, Michael A. O’Donnell, Vignesh T. Packiam	2
4	Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single‐center experience 2024 ·SHILAP Revista de lepidopterología ·(unknown), Sarah L. Mott, (unknown), (unknown), Hira Shaikh, Christopher Strouse, (unknown), Umar Farooq, Margarida Magalhaes‐Silverman	0
5	Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration 2024 ·Nature Communications ·(unknown), Jessica L. Hoffman, Sarah L. Mott, (unknown), Sema G. Quadir, (unknown), (unknown), (unknown), (unknown), Clyde W. Hodge, Melissa A. Herman	6
6	Responding to distress in cancer care: Increasing access to psycho oncology services through integrated collaborative care 2023 ·Psycho-Oncology ·(unknown), Trisha L. Raque‐Bogdan, (unknown), Sarah L. Mott, (unknown), (unknown)	2
7	A Randomized Single-Blinded Study Comparing Preoperative with Post-Mastectomy PECS Block for Post-operative Pain Management in Bilateral Mastectomy with Immediate Reconstruction 2023 ·Annals of Surgical Oncology ·Ingrid M. Lizarraga, Kaiyu Huang, (unknown), Sarah L. Mott, Zita A. Sibenaller, (unknown), Sonia L. Sugg, (unknown), (unknown)	1
8	Multimodal perioperative pain protocol for gynecologic laparotomy is associated with reduced hospital length of stay 2021 ·Journal of obstetrics and gynaecology research ·(unknown), (unknown), Sarah L. Mott, Yasmin A. Lyons, Abbey J Hardy-Fairbanks, Emily K. Hill	6
9	A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy 2021 ·Advances in Radiation Oncology ·Steven N. Seyedin, John M. Watkins, (unknown), Anthony N. Snow, (unknown), (unknown), Sarah L. Mott, Chad R. Tracy, Mark C. Smith, John M. Buatti, Joseph M. Caster	1
10	A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction 2021 ·Blood Cancer Journal ·Kalyan Nadiminti, (unknown), (unknown), Mehrdad Hefazi, (unknown), Yogesh Jethava, (unknown), Hassan B. Alkhateeb, Mark R. Litzow, Mrinal M. Patnaik, Mithun Vinod Shah, William J. Hogan, Umar Farooq, Margarida Silverman, Sarah L. Mott	2
11	A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors 2020 ·Cancer Immunology Research ·Laura M. Rogers, Zhaoming Wang, Sarah L. Mott, Adam J. Dupuy, George J. Weiner	9
12	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients 2020 ·SHILAP Revista de lepidopterología ·Namrata Singh, Sarah L. Mott, Grerk Sutamtewagul, (unknown), Susan L. Slager, James R. Cerhan, Zuhair K. Ballas, Brian K. Link	4
13	Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival 2019 ·Clinical Breast Cancer ·(unknown), (unknown), Sarah L. Mott, (unknown)	6
14	Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy 2018 ·European Journal of Cancer Care ·Varun Monga, Seth Maliske, (unknown), Sarah L. Mott, Gideon Zamba, Mohammed Milhem	12
15	Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan 2017 ·Blood ·(unknown), Sarah L. Mott, (unknown), Umar Farooq, Yogesh Jethava, Guido Tricot	0
16	Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents 2017 ·Blood ·Kalyan Nadiminti, Umar Farooq, (unknown), Sarah L. Mott, Guido Tricot, Yogesh Jethava, Margarida Silverman	0
17	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy 2016 ·Clinical Cancer Research ·Laura M. Rogers, Sarah L. Mott, Bruce A. Smith, Brian K. Link, Deniz Şahin, George J. Weiner	13
18	Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer 2015 ·Cancer Research ·Juan Du, John A. Cieslak, Jessemae L. Welsh, Zita A. Sibenaller, Bryan G. Allen, Brett A. Wagner, Amanda L. Kalen, Claire M. Doskey, (unknown), Anna M. Button, Sarah L. Mott, Bruce A. Smith, Susan Tsai, James J. Mezhir, Prabhat C. Goswami, Douglas R. Spitz, Garry R. Buettner, Joseph J. Cullen	89
19	Handover: Faster and safer 2012 ·Australian journal of advanced nursing ·(unknown), Sarah L. Mott	14
20	Leading opinions: Should nurses set national priorities for a clinical research agenda? 2004 ·Collegian Journal of the Royal College of Nursing Australia ·Helen M. Cox, Marianne Wallis, Sarah L. Mott	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact